Background
Phase 3, double-blind, placebo-controlled randomized controlled trial (iNNOVATE). N=150 patients with Waldenström's macroglobulinemia (WM) requiring therapy — treatment-naive (N=31) and previously treated (N=119). MYD88 mutation status not required for enrollment. All patients received rituximab; ibrutinib is a first-generation covalent BTK inhibitor administered continuously.
Interventions and follow up
Arm A: Ibrutinib 420 mg PO daily + rituximab 375 mg/m² IV weekly × 4 doses (cycle 1), then single doses at weeks 17, 21, 25, 29
Arm B: Placebo PO daily + rituximab (same schedule)
Primary endpoint: Progression-free survival (PFS)
Median follow-up: 26.5 months (primary); 63 months (long-term update, Lancet Oncol 2020)
Arm B: Placebo PO daily + rituximab (same schedule)
Primary endpoint: Progression-free survival (PFS)
Median follow-up: 26.5 months (primary); 63 months (long-term update, Lancet Oncol 2020)
Results
30-mo PFS rate: 82% vs 28% (ibrutinib+R vs placebo+R), HR 0.20 (95% CI 0.11–0.34), P<.001
ORR: 92% vs 47%
≥VGPR: 30% vs 7%
Rituximab IgM flare: 8% (ibrutinib+R) vs 47% (placebo+R)
Long-term PFS (63 mo): HR 0.25 (95% CI 0.14–0.43)
ORR: 92% vs 47%
≥VGPR: 30% vs 7%
Rituximab IgM flare: 8% (ibrutinib+R) vs 47% (placebo+R)
Long-term PFS (63 mo): HR 0.25 (95% CI 0.14–0.43)
Adverse events
Cardiovascular: Atrial fibrillation any grade 15% (ibrutinib) vs 3% (placebo), grade ≥3 12% vs 1%; hypertension grade ≥3 13% vs 4%
Bleeding/GI: Major hemorrhage any grade 4% vs 1%; diarrhea any grade 37% vs 18%
Discontinuation: Due to AEs 20% (ibrutinib) vs 8% (placebo)
Bleeding/GI: Major hemorrhage any grade 4% vs 1%; diarrhea any grade 37% vs 18%
Discontinuation: Due to AEs 20% (ibrutinib) vs 8% (placebo)
Conclusions
Ibrutinib + rituximab significantly improved PFS and response rates vs placebo + rituximab in WM, preventing the rituximab-associated IgM flare and establishing BTK inhibitor-based therapy as a preferred treatment for symptomatic WM. Benefit was sustained at 5-year follow-up (HR 0.25).
Key Limitations
The placebo + rituximab comparator has limited clinical relevance (rituximab monotherapy is rarely used as definitive WM therapy); the striking PFS advantage partly reflects poor activity of rituximab alone and the rituximab IgM flare. MYD88 wild-type patients had substantially lower benefit from ibrutinib — a critical limitation underrepresented in the primary analysis. Atrial fibrillation risk (15%) limits use in patients with pre-existing cardiac disease. Zanubrutinib (ASPEN) subsequently demonstrated equivalent efficacy with markedly lower AFib risk (2.5% vs 15.3%).
Clinical Context
Ibrutinib + rituximab is FDA-approved (2018) for treatment-naive and R/R WM. However, zanubrutinib monotherapy has largely supplanted ibrutinib-based regimens at many centers given its superior cardiac safety profile (ASPEN trial). For MYD88 wild-type patients, chemoimmunotherapy (bendamustine-rituximab, DRC) or bortezomib-based regimens are preferred given limited BTKi benefit. ESMO-MCBS: not assigned for WM trials.